B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression

Blood

Volumn 101, Issue 7, 2003, Pages 2514-2520

  Trabattoni, Daria ^b   Saresella, Marina ^b   Biasin, Mara ^b   Boasso, Adriano ^b   Piacentini, Luca ^b   Ferrante, Pasquale ^b   Dong, Haidong ^b   Maserati, Renato ^b   Shearer, Gene M ^b   Chen, Lieping ^b   Clerici, Mario ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; B7 ANTIGEN; BIOLOGICAL MARKER; CD14 ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 10; MESSENGER RNA; PROTEIN; PROTEIN B7H1; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; COMPLEMENTARY DNA; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; PEPTIDE; PLASMA PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC THERAPY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LYMPHOCYTE COUNT; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; T LYMPHOCYTE; UPREGULATION; VIREMIA; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY;

ANTIGENS, CD; ANTIGENS, CD80; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DNA, COMPLEMENTARY; HIV INFECTIONS; HUMANS; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; MEMBRANE GLYCOPROTEINS; PEPTIDES; RNA, MESSENGER; UP-REGULATION;

EID: 0038784354     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3065     Document Type: Article

References (59)

1. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T cell activation. Cell. 1994;76:287-299.
2. Freemont DH, Rees WA, Kozono H. Biophysical studies of T cell receptors and their ligands. Curr Opin Immunol. 1996;8:93-100.
3. Chambers CA. Allison JP. Costimulation in T cell responses. Curr Opin Immunol. 1997;9:396-404.
4. Bugeon L, Dallman LJ. Costimulation of T cells. Am J Respir Crit Care Med. 2000;62:S164-168.
5. Lencschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258.
6. Freeman GJ, Freeman AS, Segll JM. B7 a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989;143:2714-2720.
7. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365-1369.
8. Wang S, Zhu G, Chapoval AI, et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood. 2000;96:2808-2813.
9. Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFNγ production. Nat Immunol. 2001;2:269-274.
10. Freeman GJ. Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-1034.
11. Nishimura H, Honjo T. PD-1 an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2000;22:265-268.
12. Tamura H, Dong H, Zhu G, et al. B7-H1 costimulation preferentially enhances CD28-independent T helper cell function. Blood. 2000;97:1809-1816.
13. Clerici M, Wynn TA, Berzofsky JA, et al. Role of interleukin-10 (IL-10) in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus (HIV-1). J Clin Invest. 1994;93:768-775.
14. Klein SA, Dobmeyer JM, Dobmeyer TS, et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS. 1997;11:1111-1118.
15. Clerici M, Balotta C, Salvaggio A, et al. Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood. 1996;88:574-579.
16. Ostrowski MA, Gu JX, Kovacs C, Freedman J, Luscher M-A, MacDonald KS. Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses. J Inf Dis. 2001;184:1268-1278.
17. Miedema F, Petit AJ, Terpstra FG, et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men, HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest. 1988;82:1908-1915.
18. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ call numbers and clinical staging. J Clin Invest. 1989;84:1892-1899.
19. Blatt SP, Hendrix CW, Butzin CA, et al. Delayed type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Int Med. 1993;119:177-188.
20. Markowitz N, Hansen NI, Wilcosky TC, et al. Tubercolin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Int Med. 1993:119:185-192.
21. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature. 1996;384:529-534.
22. Shearer GM. HIV-induced immunopathogenesis. Immunity. 1998:9:587-596.
23. Clerici M, Shearer GM. A TH1-TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14:107-113.
24. Clerici M, Shearer GM. The Th1/Th2 theory of HIV infection: new insights. Immunol Today. 1994;15:575-582.
25. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
26. Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology. 2001;103:131-148.
27. Amirayan-Chevillard N, Tissotdupont H. Capo C, et al. Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients. Clin Exp Immunol. 2000;120:107-112.
28. Imami N, Antonopoulos C, Hardy GA, Gazzard B, Gotch F-M. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Human Retroviruses. 1999;15:1499-508.
29. Stylianou E, Aukrust P, Kvale D, Muller F, Froland SS. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression-down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol. 1999;116:115-120.
30. Taoufik Y, Peguillet I, de Goer MG, et al. Effect of highly active antiretroviral therapy on expression of interleukin-10 and interleukin-12 in HIV-infected patients. J Acquir Immune Defic Syndr. 2001;26:303-304.
31. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-I and inhibits T cell activation. Nat Immunol. 2001;2:261-268.
32. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002:8:777-788.
33. Smith DR, Kunkel SL, Burdick MD, et al. Production of IL-10 by human bronchogenic carcinoma. Am J Pathol. 1995;145:18-25.
34. Nakagomi H, Pisa P, Pisa EK, et al. Lack of IL-2 expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer. 1995;63:366-377.
35. Kim J, Modlin RL, Moy RL, et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol. 1995;155:2240-2247.
36. Rennick DM, Fort MM, Davidson NJ. Studies with IL-10-/- mice: an overview. J Leuk Biol. 1997;61:389-396.
37. Davidson NJ, Fort MM, Muller W, Leach MW, Rennick DM. Chronic colitis in IL-10-/- mice: insufficient counter regulation of a Th1 response. Int Rev Immunol. 2000;19:91-121.
38. Groux H, Powrie F. Regulatory T cells and inflammatory bowel disease. Immunol Today. 1999;20:442-445.
39. Clerici M, Stocks NI, Zajac RA, Boswell RN, Shearer GM. Accessory cell function in asymptomatic, human immunodeficiency virus infected patients. Clin Immunol Immunopathol. 1990;58:168-173.
40. Blauvelt A, Cierici M, Lucey DL, Shearer GM, Katz S. Functional studies of epidermal Langherans cells and blood monocytes in human immunodeficiency virus-infected individuals. J Immunol. 1995;154:3506-3515.
41. Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today. 1991:12:102-106.
42. Gougeon ML, Garcia S, Heeney J. Programmed cell death in AIDS-related HIV and SIV infections. AIDS Res Hum Retroviruses. 1993;9:553-560.
43. Oyaizu N, Pahwa S. Role of apoptosis in HIV disease pathogenesis. J Clin Immunol. 1995;15:27-231.
44. Clerici M, Sarin A, Coffman RL, et al. Type1/type2 cytokine modulation of T cell programmed cell death as a model for HIV pathogenesis. Proc Natl Acad Sci U S A. 1994;91:11811-11815.
45. Carter LL, Fouser LA, Jussif J, et al. PD-1/PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol. 2002;32:634-643.
46. Sozzani S, Ghezzi S, Lannolo G, et al. Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med. 1998;187:439-444.
47. Houle M, Thivierge M, Le Gouill C, Stankova J, Rola-Pleszczynski M. IL-10 up-regulates CCR5 gene expression in human monocytes. Inflammation. 1999;23:241-251.
48. Wang J, Crawford K, Yuan M, Wang H, Gorry PR, Gabuzda D. Regulation of CC chemokine receptor 5 and CD4 expression and human immunodeficiency virus type 1 replication in human macrophages and microglia by T helper type 2 cytokines. J Inf Dis. 2002;185:885-897.
49. Ancuta P, Bakri Y, Chomont N, Hocini H, Gabuzda D, Haeffner-Cacallion N. Opposite effect of IL-10 on the ability of dendritic cells and macrophages to replicate CXCR4-dependent HIV strains. J Immunol. 2001;166:4244-4253.
50. Kumar A, Angel JB, Daftarian MP, et al. Differential production of IL-10 by T cells and monocytes of HIV-infected individuals: association of IL-10 production with CD28-mediated immune responsiveness. Clin Exp Immunol. 1998;114:78-86.
51. Cua DJ, Hutchins B, LaFace DM, Stohlman S-A, Coffman RL. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Immunol. 2001;166:602-608.
52. Cua DJ, Groux H, Hinton DR, Stohlman SA, Coffman RL. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J Exp Med. 1999;189:1005-1010.
53. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med. 1996;184:19-29.
54. Levings M-K, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo MG. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol. 2001;166:5530-5539.
55. Groux H, Bigler M, de Vries J-E, Roncarolo M-G. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol. 1998:160:3188-3193.
56. Nishimura H, Nose M. Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141-151.
57. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319-322.
58. Ng V-L. B-lymphocyles and autoantibody profiles in HIV disease. Clin Rev Allergy Immunol. 1997;14:367-384.
59. Poudrier J, Weng X, Kay DG, et al. The AiDS disease of CD4C/HIV transgenic mice shows impaired germinal centers and autoantibodies and develops in the absence of IFN-gamma and IL-6. Immunity. 2001;15:173-185.